Xi'an Manareco(SH:688550) Tianfeng Securities·2025-06-18 03:16Investment Rating - The report maintains a "Buy" rating for the company, with an expected relative return of over 20% within the next six months [6][18]. Core Insights - The company achieved a revenue of 1.459 billion yuan in 2024, representing a year-on-year increase of 20.7%, and a net profit attributable to the parent company of 252 million yuan, up 87.6% year-on-year [1][2]. - The display materials segment has become the largest business area for the company, driven by the increasing penetration of OLED panels in medium and large-sized screens [2][3]. - The pharmaceutical segment is focusing on stable supply and new product development amidst a competitive market, with a total of 271 drug pipelines by the end of 2024, an increase of 64 from the previous year [2][3]. - The electronic materials segment faced challenges due to technological substitutions and cautious customer procurement strategies, leading to a decline in sales, although the number of products sold increased by 72% year-on-year [3]. - The overall gross margin for 2024 was 44.20%, an increase of 9.02 percentage points from 2023, attributed to product mix optimization and effective cost control measures [3]. Financial Summary - The company forecasts net profits of 313 million yuan, 367 million yuan, and 400 million yuan for 2025, 2026, and 2027 respectively, reflecting an upward revision from previous estimates [3]. - The projected revenue growth rates for the next few years are 36.93% for 2025, 20.53% for 2026, and 6.90% for 2027 [5][12]. - The earnings per share (EPS) are expected to increase from 1.46 yuan in 2024 to 2.32 yuan in 2027 [5][12].